CN
CNTB.US Connect Biopharma Holdings Ltd
- Market cap
- USD 42.6M
- P/E
- -
- P/B
- 1.61x
- ROE
- -273.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is CNTB.US undervalued?
Graham numberThe Graham number of Connect Biopharma Holdings Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Connect Biopharma Holdings Ltd fundamental analysis
No fundamental analysis for Connect Biopharma Holdings Ltd yet.
Connect Biopharma Holdings Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Connect Biopharma Holdings Ltd
Connect Biopharma Holdings Limited operates as a clinical-stage biopharmaceutical company in the United States. It develops rademikibart, a human monoclonal IgG4 antibody directed against IL-4Ra in two Phase 2 trials for the treatment of acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD). The company was founded in 2012 and is headquartered in San Diego, California.
Full company profileConnect Biopharma Holdings Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Connect Biopharma Holdings Ltd annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 26.0M | 64.0K | 5.87M |
| Gross Profit | - | - | - | - | -1.03M | -988K | 26.0M | 64.0K | - |
| Operating Income | - | -16.0M | -30.3M | -98.1M | -119M | -69.1M | -22.5M | -58.1M | -74.4M |
| EBITDA | - | -24.8M | -118M | -201M | -117M | -61.3M | -14.7M | -54.6M | -73.3M |
| Net Income | - | -24.5M | -119M | -202M | -118M | -62.1M | -15.6M | -55.5M | -73.4M |
| EPS | - | -0.44 | -2.21 | -3.87 | -2.15 | -1.13 | -0.28 | -1.00 | -1.17 |
| Balance Sheet | |||||||||
| Total Assets | 69.3M | 7.73M | 25.4M | 291M | 174M | 127M | 101M | 56.1M | 43.5M |
| Total Liabilities | 88.7M | 13.9M | 49.5M | 18.8M | 16.5M | 25.9M | 9.12M | 14.1M | 16.6M |
| Shareholders' Equity | -19.4M | -6.18M | -24.0M | 272M | 157M | 101M | 92.2M | 42.0M | 26.9M |
| Cash & Short-term Investments | 65.9M | 7.04M | 24.0M | 268M | 152M | 118M | 93.7M | 44.3M | 31.5M |
| Total Debt | 87.7M | 18.3K | 21.4K | 125K | 431K | 465K | 178K | 690K | 596K |
| Cash Flow | |||||||||
| Operating Cash Flow | -69.0M | -13.1M | -25.6M | -545M | -99.3M | -47.9M | -23.6M | -51.2M | -95.9M |
| Capital Expenditure | 1.19M | 156K | 2.34M | 47.5M | 4.28M | 294K | 750K | 434K | 32.0K |
| Free Cash Flow | - | -13.2M | -28.0M | -592M | -104M | -48.2M | -24.4M | -51.6M | -73.3M |
| Ratios | |||||||||
| ROE | - | - | - | -74.3% | -75.0% | -61.2% | -17.0% | -132.2% | -273.1% |
| ROA | - | -316.7% | -469.3% | -69.5% | -67.9% | -48.8% | -15.4% | -98.9% | -168.8% |
| Net Profit Margin | - | - | - | - | - | - | -60.0% | -86,687.5% | -1,249.0% |
| Debt to Equity | - | - | - | 0.00x | 0.00x | 0.00x | 0.00x | 0.02x | 0.02x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Connect Biopharma Holdings Ltd dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | CNY 243K | 0.00 | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Connect Biopharma Holdings Ltd
- Insiders 30.35%
- Institutions 56.88%
- Public & others 12.78%
- Shares outstanding 63.0M
- Free float 22.1M
Top funds holding CNTB.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| T. Rowe Price Small-Cap Index I | 2.28K | 0.00% | 0.00% | Jun 2026 |
Top institutions holding CNTB.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Quadrature Capital Limited | 42.3K | 0.07% | 0.00% | Jun 2026 |
| EverSource Wealth Advisors, LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
Connect Biopharma Holdings Ltd company profile
- Company name
- Connect Biopharma Holdings Ltd
- Ticker
- CNTB.US
- ISIN
- KYG235491019
- Exchange
- USA Stocks
- Listed since
- Mar 19, 2021
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 64
- Fiscal year end
- December
- Address
- 3580 Carmel Mountain Road, San Diego, CA, United States, 92130
- Phone
- 877 245 2787
- Website
- connectbiopharm.com
About Connect Biopharma Holdings Ltd
Connect Biopharma Holdings Limited operates as a clinical-stage biopharmaceutical company in the United States. It develops rademikibart, a human monoclonal IgG4 antibody directed against IL-4Ra in two Phase 2 trials for the treatment of acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD). The company was founded in 2012 and is headquartered in San Diego, California.
Connect Biopharma Holdings Ltd management
8- Dr. Barry David Quart Pharm.D.CEO & Director · born 1957
- Mr. David L. Szekeres J.D.President · born 1974
- Ms. Lisa Peraza CPASenior Vice President of Finance · born 1977
- Mr. Jeff Cohn J.D.General Counsel & Corporate Secretary · born 1982
- Mr. Sean T. RistineVice President of Human Resources · born 1970
- Dr. Lei Sun Ph.D.VP of Biologics & Head of CMC · born 1964
- Dr. Srikanth Pendyala M.D.Senior Vice President of Clinical Development(Consultant)
- Ms. Kimberly J. ManhardExecutive VP & Chief Development Officer · born 1960